ATE495154T1 - Pharmazeutische zusammensetzungen, die ccr5- antagonisierende piperazinderivate enthalten - Google Patents

Pharmazeutische zusammensetzungen, die ccr5- antagonisierende piperazinderivate enthalten

Info

Publication number
ATE495154T1
ATE495154T1 AT05010936T AT05010936T ATE495154T1 AT E495154 T1 ATE495154 T1 AT E495154T1 AT 05010936 T AT05010936 T AT 05010936T AT 05010936 T AT05010936 T AT 05010936T AT E495154 T1 ATE495154 T1 AT E495154T1
Authority
AT
Austria
Prior art keywords
antagonizing
pharmaceutical compositions
compositions containing
piperazine derivatives
containing ccr5
Prior art date
Application number
AT05010936T
Other languages
English (en)
Inventor
Bahige M Baroudy
John W Clader
Huber B Josien
Stuart W Mccombie
Brian A Mckittrick
Michael W Miller
Bernard R Neustadt
Anandan Palani
Ruo Steensma
Jayaram R Tagat
Susan F Vice
Mark A Laughlin
Elizabeth M Smith
Eric Gilbert
Marc A Labroli
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23179892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE495154(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE495154T1 publication Critical patent/ATE495154T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05010936T 1999-05-04 2000-05-01 Pharmazeutische zusammensetzungen, die ccr5- antagonisierende piperazinderivate enthalten ATE495154T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30522699A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
ATE495154T1 true ATE495154T1 (de) 2011-01-15

Family

ID=23179892

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00926486T ATE299865T1 (de) 1999-05-04 2000-05-01 Piperazinderivate verwendbar als ccr5 antagonisten
AT05010936T ATE495154T1 (de) 1999-05-04 2000-05-01 Pharmazeutische zusammensetzungen, die ccr5- antagonisierende piperazinderivate enthalten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00926486T ATE299865T1 (de) 1999-05-04 2000-05-01 Piperazinderivate verwendbar als ccr5 antagonisten

Country Status (31)

Country Link
EP (2) EP1632479B1 (de)
JP (2) JP3722700B2 (de)
KR (1) KR100439358B1 (de)
AR (5) AR023823A1 (de)
AT (2) ATE299865T1 (de)
AU (2) AU780888B2 (de)
BR (1) BR0010304A (de)
CA (1) CA2371583C (de)
CH (1) CH1175401H9 (de)
CL (1) CL2008002737A1 (de)
CO (1) CO5170523A1 (de)
CZ (1) CZ20013940A3 (de)
DE (2) DE60045528D1 (de)
DK (1) DK1175401T3 (de)
EG (1) EG24136A (de)
ES (1) ES2244437T3 (de)
HK (1) HK1039930B (de)
HU (1) HUP0202867A3 (de)
IL (1) IL145741A0 (de)
MY (1) MY128367A (de)
NO (1) NO322045B1 (de)
PE (1) PE20010150A1 (de)
PL (1) PL203116B1 (de)
RU (1) RU2299206C9 (de)
SA (2) SA06270096B1 (de)
SI (1) SI1175401T1 (de)
SK (2) SK287418B6 (de)
TR (1) TR200103214T2 (de)
TW (1) TWI285200B (de)
WO (1) WO2000066558A1 (de)
ZA (1) ZA200108868B (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) * 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
KR100613528B1 (ko) 2001-03-29 2006-08-16 쉐링 코포레이션 Ｃｃｒ5 길항제, 및 이를 포함하는 약제학적 조성물 및 키트
CN1253435C (zh) 2001-03-29 2006-04-26 先灵公司 可用作ccr5拮抗剂的芳基肟－哌嗪
EP1451174B1 (de) * 2001-11-29 2010-08-18 Schering Corporation Verfahren zur herstellung von zusammensetzungen mit erhöhtem gehalt von salzen pharmazeutisch aktiver rotamere
EP2311818B1 (de) 2002-02-28 2013-01-16 Novartis AG Kombination aus einem 5-phenylthiazolderivat als PI3-Kinasehemmer und eine entzündungshemmender, bronchodilatatorische oder antihistaminischen Verbindung
JP4671091B2 (ja) * 2002-03-18 2011-04-13 東レ・ファインケミカル株式会社 １−置換−２−メチルピペラジンの製造方法
CN101092401A (zh) * 2002-03-29 2007-12-26 先灵公司 手性2－甲基－4－保护的哌嗪的立体选择性烷基化
CA2480482A1 (en) * 2002-03-29 2003-10-16 Schering Corporation Synthesis of piperidine and piperazine compounds as ccr5 antagonists
CA2483253A1 (en) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
JP2003335737A (ja) 2002-05-21 2003-11-28 Central Glass Co Ltd 光学活性（ｒ）−１−（４−トリフルオロメチルフェニル）エチルアミン
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1570860A4 (de) * 2002-12-13 2009-06-03 Ono Pharmaceutical Co Antagonisten- und agonistenbindung an die stark bindende stelle des chemokinrezeptors
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US20070043079A1 (en) * 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
EP1619193A4 (de) 2003-04-18 2010-08-11 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process
MXPA05013474A (es) * 2003-06-13 2006-03-09 Schering Ag Derivados de quinolilamida como antagonistas de ccr-5.
US7345042B2 (en) 2003-06-30 2008-03-18 Schering Corporation MCH antagonists for the treatment of obesity
CN1898231B (zh) 2003-11-03 2010-10-27 先灵公司 用作趋化因子受体抑制剂的双六氢吡啶衍生物
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2324224T3 (es) * 2004-02-05 2009-08-03 Schering Corporation Derivados de piperidina que se pueden utilizar como antagonistas ccr3.
AU2005211499A1 (en) * 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine CCR5 receptor modulators
WO2005085216A1 (ja) 2004-03-05 2005-09-15 Nissan Chemical Industries, Ltd. イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤
HU229709B1 (en) 2004-04-13 2014-05-28 Incyte Corp Wilmington Piperazinyilpiperidine derivatives as chemokine receptor antagonists
DK1761542T3 (da) 2004-06-09 2008-04-28 Hoffmann La Roche Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler
GB0417804D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7521452B2 (en) 2005-01-06 2009-04-21 Schering Corporation Preparation of pharmaceutical salts of piperazine compounds
MX2007010068A (es) 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
CN101146793A (zh) 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
US7566718B2 (en) * 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
EP1856097B1 (de) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl- and phenylsubstituierte piperazinpiperidine mit cxcr3-antagonistenaktivität
KR20070107060A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 피라지닐 치환된피페라진-피페리딘
CN101163695A (zh) * 2005-02-23 2008-04-16 先灵公司 用作趋化因子受体抑制剂的哌啶基哌嗪衍生物
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
PT1893603E (pt) 2005-06-02 2009-11-24 Hoffmann La Roche Derivados de piperidin-4-il-amida e a sua utilização como antagonistas do receptor de sst do subtipo 5
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
WO2007064620A2 (en) * 2005-11-30 2007-06-07 Schering Corporation Compositions comprising a combination of ccr5 and cxcr4 antagonists
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
RU2008133381A (ru) 2006-01-18 2010-02-27 Шеринг Корпорейшн (US) Модуляторы каннабиноидного рецептора
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
JP5373599B2 (ja) 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
PT2057125E (pt) 2006-08-16 2011-05-31 Hoffmann La Roche Inibidores n?o nucle?sidos de transcriptase inversa
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
KR101475091B1 (ko) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
BRPI0720799A2 (pt) 2007-01-10 2014-03-11 Irm Llc Compostos e composições como inibidores de protease de ativação de canal.
CN101657430B (zh) * 2007-03-15 2013-05-01 诺瓦提斯公司 有机化合物及其用途
CA2682639A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
JP2010540584A (ja) 2007-10-01 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ受容体アンタゴニストとしてのｎ−複素環ビアリールカルボキサミド類
CA2707857C (en) 2007-12-10 2016-09-13 Novartis Ag Spirocyclic amiloride analogues
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8367674B2 (en) 2008-04-17 2013-02-05 Concert Pharmaceuticals, Inc. Piperazine derivatives
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
MA33085B1 (fr) 2008-12-19 2012-03-01 Boehringer Ingelheim Int Pyrimidine-4 carboxamides cycliques en tant qu'antagonistes du recepteur ccr2 pour le traitement d'inflammations, de l'asthme et des broncho-pneumopathies chroniques obstructives
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
JP5658272B2 (ja) * 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
JP5632014B2 (ja) 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト及びこれらの使用
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
EP2571870B1 (de) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2-antagonisten und verwendungen dafür
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
CN103097385B (zh) 2010-07-14 2016-08-03 诺华股份有限公司 Ip受体激动剂杂环化合物
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
EP2741777B1 (de) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von pulmonaler hypertonie
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
EP2802582A1 (de) 2012-01-13 2014-11-19 Novartis AG Annelierte dihydropyrido-[2,3 -b]pyrazine als ip-rezeptoragonisten zur behandlung von pulmonaler arterieller hypertonie (pah) und dadurch vermittelten erkrankungen
EP2802585A1 (de) 2012-01-13 2014-11-19 Novartis AG Kondensierte piperidine als ip-rezeptoragonisten zur behandlung von pah und verwandten erkrankungen
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802581A1 (de) 2012-01-13 2014-11-19 Novartis AG 7,8-dihydropyrido-[3,4, b-]pyrazine als ip-rezeptoragonisten zur behandlung von pulmonaler arterieller hypertonie (pah) und zugehörigen erkrankungen
US9174985B2 (en) 2012-01-13 2015-11-03 Novartis Ag Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
EP3134397A1 (de) 2014-04-24 2017-03-01 Novartis AG Aminopyrazinderivate als phosphatidylinositol-3-kinasehemmer
JP6454727B2 (ja) 2014-04-24 2019-01-16 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピリジン誘導体
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (de) 2014-07-31 2020-08-19 Novartis AG Kombinationstherapie von einem met-hemmer und einem egfr-hemmer
WO2016028971A1 (en) * 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
EP3317270B1 (de) 2015-07-02 2020-05-13 Centrexion Therapeutics Corporation (4-((3r,4r) -3-methoxytetrahydro-pyran-4-ylamino ) piperidin-1-yl)-(5-methyl-6-(( (2r,6s) -6-(p-tolyl) tetrahydro-2 h-pyran-2-yl) methylamino) pyrimidin-4 yl) methanon-citrat
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
DE69919171T2 (de) * 1998-06-30 2005-08-04 Schering Corp. Muskarin-rezeptor antagonisten

Also Published As

Publication number Publication date
EG24136A (en) 2008-08-06
NO322045B1 (no) 2006-08-07
AU2005202357A1 (en) 2005-06-23
CA2371583C (en) 2005-09-13
HK1039930A1 (en) 2002-05-17
IL145741A0 (en) 2002-07-25
DE60021370T2 (de) 2006-04-27
RU2299206C9 (ru) 2007-11-20
MY128367A (en) 2007-01-31
AR023823A1 (es) 2002-09-04
CH1175401H9 (de) 2007-03-30
PE20010150A1 (es) 2001-02-09
PL203116B1 (pl) 2009-08-31
TWI285200B (en) 2007-08-11
SK286641B6 (sk) 2009-03-05
AU2005202357B2 (en) 2009-04-02
CA2371583A1 (en) 2000-11-09
RU2299206C2 (ru) 2007-05-20
AR057106A2 (es) 2007-11-14
KR100439358B1 (ko) 2004-07-07
PL351388A1 (en) 2003-04-07
SK287418B6 (sk) 2010-09-07
KR20020019907A (ko) 2002-03-13
TR200103214T2 (tr) 2002-03-21
ZA200108868B (en) 2003-01-27
SK15692001A3 (sk) 2002-07-02
HUP0202867A2 (hu) 2003-01-28
SA06270096B1 (ar) 2009-02-25
CO5170523A1 (es) 2002-06-27
EP1175401B1 (de) 2005-07-20
AR057786A2 (es) 2007-12-19
JP2002543185A (ja) 2002-12-17
AU780888B2 (en) 2005-04-21
EP1632479A3 (de) 2007-05-09
JP2006052225A (ja) 2006-02-23
CH1175401H1 (de) 2007-02-15
EP1632479A2 (de) 2006-03-08
HK1039930B (zh) 2005-12-09
ES2244437T3 (es) 2005-12-16
EP1175401A1 (de) 2002-01-30
DK1175401T3 (da) 2005-11-14
AR057107A2 (es) 2007-11-14
CZ20013940A3 (cs) 2002-04-17
JP3722700B2 (ja) 2005-11-30
CL2008002737A1 (es) 2009-01-16
DE60021370C5 (de) 2007-11-08
DE60021370D1 (de) 2005-08-25
SA00210271B1 (ar) 2006-07-30
ATE299865T1 (de) 2005-08-15
HUP0202867A3 (en) 2004-01-28
AR057873A2 (es) 2007-12-26
NO20015366L (no) 2002-01-03
AU4500900A (en) 2000-11-17
WO2000066558A1 (en) 2000-11-09
EP1632479B1 (de) 2011-01-12
DE60045528D1 (de) 2011-02-24
BR0010304A (pt) 2002-02-13
SI1175401T1 (en) 2005-10-31
NO20015366D0 (no) 2001-11-02

Similar Documents

Publication Publication Date Title
DE60045528D1 (de) Pharmazeutische zusammensetzungen, die ccr5-antagonisierende piperazinderivate enthalten
HUP0203528A3 (en) Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
HUP0202787A3 (en) Piperazine derivatives as 5-ht1b antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0204515A3 (en) 4-aminopiperidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0105114A3 (en) Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation
IS2448B (is) Pýrasólkarboxýlsýruafleiður, framleiðsla þeirra, lyfjasamsetningar sem innihalda þær
HUP0203548A3 (en) New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204245A3 (en) Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use
IL150225A0 (en) Lipopeptides, pharmaceutical compositions containing the same and methods for the production thereof
HUP0300618A3 (en) Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0303082A3 (en) Substituted indoleoxoacetic piperazine derivatives, pharmaceutical compositions containing them and their antiviral use
HUP0203320A3 (en) Indolylpiperidine derivatives and their use as antihistaminic and antiallergic agents, process for their preparation, pharmaceutical compositions containing them
HUP0202075A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203385A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0203645A3 (en) Phenylpiperazinyl derivatives, pharmaceutical compositions containing them and their use
HUP0200281A2 (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists, process for their preparation and pharmaceutical compositions containing them
IL180579A0 (en) Piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
HK1052007A1 (en) Novel heterocyclic derivatives, preparation methodand pharmaceutical compositions containing same.
HUP0203839A3 (en) 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives, pharmaceutical compositions containing them and their use
HUP0303673A3 (en) Piperidine derivatives and pharmaceutical compositions containing these derivatives as the active ingredient
HUP0201315A3 (en) 4-phenyl-pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
EE04525B1 (et) Morfoliini derivaadid, nende valmistamismeetod janeid sisaldavad farmatseutilised kompositsioonid
HUP0201797A3 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE60200023D1 (de) Isoindoloindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltende pharmazeutische Zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties